Unleashing the power of precision medicine: Beyond oncology

In 2023, 12 precision medicine related treatments were approved, as well as six biomarker and an indication that specific treatments were included in the National Comprehensive Cancer Network (NCCN) guidelines. These breakthrough precision oncology therapies had a significant impact on patient outcomes — such as the recent approval of quizartinib earlier in 2023, a more potent FMS‐like tyrosine kinase 3 (FLT3) and FLT3-internal tandem duplication (FLT3-ITD) mutation type II inhibitor compared with earlier generation FLT3 inhibitors. Patients with acute myeloid leukemia (AML) that received quizartinib in addition to first-line chemotherapy achieved a median overall survival of 31.9 months compared with 15.1 months in patients who received first-line chemotherapy alone while significantly improving quality of life for these patients. While the short-term focuses on cancer-centric strides, the long-term vision promises a sweeping impact across a spectrum of diseases. <a href="https://medium.com/zs-associates/unleashing-the-power-of-precision-medicine-beyond-oncology-cc9e7e5cd08c">Visit Now</a>